R Fernandes1, S Mazzarello2, A A Joy3, G R Pond4, J Hilton1,2, M F K Ibrahim1, C Canil1,2, M Ong1,2, C Stober1, L Vandermeer2, B Hutton2,5, M da Costa1, S Damaraju6, Mark Clemons7,8,9. 1. Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada. 2. Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada. 3. Department of Oncology, Division of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada. 4. McMaster University and Ontario Clinical Oncology Group, Hamilton, ON, Canada. 5. Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada. 6. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada. 7. Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada. mclemons@toh.ca. 8. Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada. mclemons@toh.ca. 9. The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. mclemons@toh.ca.
Abstract
BACKGROUND: Taxane acute pain syndrome (TAPS) is characterized by myalgias and arthralgias starting 2-3 days after taxane-based chemotherapy and lasting up to 7 days. In the absence of validated tools, many studies use the presence of both the myalgia and arthralgia components of the Common Terminology Criteria for Adverse Events (CTCAE) to define TAPS. The present study prospectively evaluated the frequency, severity, and impact of TAPS in patients with breast or prostate cancer. PATIENTS AND METHODS: In this prospective, non-randomized study, patients with breast or prostate cancer commencing taxane-based chemotherapy completed the CTCAE (version 4.03), the Functional Assessment of Cancer Therapy-Taxane (FACT-T), and Brief Pain Inventory (BPI) questionnaires at baseline and once between days 5 and 7 of each chemotherapy cycle. RESULTS: From March 2015 to April 1, 2016, 75 patients (breast n = 66, prostate n = 9) were enrolled; 83% received docetaxel and 16% paclitaxel and 1% withdrew. After the first cycle of taxane, TAPS was reported by 25/69 (36.2%) patients; a further 8/69 (18.2%) reporting TAPS after a subsequent chemotherapy treatment. Overall incidence of TAPS was 33/75 (44%). While associated with detrimental scores on FACT-T and BPI as well as increased use of analgesics in 63% (21/33) of patients with TAPS, TAPS did not lead to alterations in chemotherapy dosing. CONCLUSIONS: TAPS is common after taxane-based chemotherapy, and its presence is associated with reduced quality of life and increased analgesic requirements. Prospective patient-reported outcome assessments are crucial to help individualize treatment strategies and improve management of TAPS.
BACKGROUND:Taxaneacute pain syndrome (TAPS) is characterized by myalgias and arthralgias starting 2-3 days after taxane-based chemotherapy and lasting up to 7 days. In the absence of validated tools, many studies use the presence of both the myalgia and arthralgia components of the Common Terminology Criteria for Adverse Events (CTCAE) to define TAPS. The present study prospectively evaluated the frequency, severity, and impact of TAPS in patients with breast or prostate cancer. PATIENTS AND METHODS: In this prospective, non-randomized study, patients with breast or prostate cancer commencing taxane-based chemotherapy completed the CTCAE (version 4.03), the Functional Assessment of Cancer Therapy-Taxane (FACT-T), and Brief Pain Inventory (BPI) questionnaires at baseline and once between days 5 and 7 of each chemotherapy cycle. RESULTS: From March 2015 to April 1, 2016, 75 patients (breast n = 66, prostate n = 9) were enrolled; 83% received docetaxel and 16% paclitaxel and 1% withdrew. After the first cycle of taxane, TAPS was reported by 25/69 (36.2%) patients; a further 8/69 (18.2%) reporting TAPS after a subsequent chemotherapy treatment. Overall incidence of TAPS was 33/75 (44%). While associated with detrimental scores on FACT-T and BPI as well as increased use of analgesics in 63% (21/33) of patients with TAPS, TAPS did not lead to alterations in chemotherapy dosing. CONCLUSIONS:TAPS is common after taxane-based chemotherapy, and its presence is associated with reduced quality of life and increased analgesic requirements. Prospective patient-reported outcome assessments are crucial to help individualize treatment strategies and improve management of TAPS.
Entities:
Keywords:
Breast cancer; Prostate cancer; Quality of life; Taxane; Taxane acute pain syndrome
Authors: Nicholas Chiu; Liying Zhang; Rebecca Dent; Angie Giotis; Jenna van Draanen; Daniela Gallo-Hershberg; Leonard Chiu; Ronald Chow; Bo Angela Wan; Mark Pasetka; Jordan Stinson; Erica Stacey; Sunil Verma; Henry Lam; Edward Chow; Carlo DeAngelis Journal: Support Care Cancer Date: 2017-07-22 Impact factor: 3.603
Authors: Charles L Loprinzi; Brandi N Reeves; Shaker R Dakhil; Jeff A Sloan; Sherry L Wolf; Kelli N Burger; Arif Kamal; Nguyet A Le-Lindqwister; Gamini S Soori; Anthony J Jaslowski; Paul J Novotny; Daniel H Lachance Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544
Authors: Roy E Smith; Stewart J Anderson; Ann Brown; Aaron P Scholnik; Ajit M Desai; Carl G Kardinal; Barry C Lembersky; Eleftherios P Mamounas Journal: Clin Breast Cancer Date: 2002-12 Impact factor: 3.225
Authors: R K Portenoy; H T Thaler; A B Kornblith; J M Lepore; H Friedlander-Klar; E Kiyasu; K Sobel; N Coyle; N Kemeny; L Norton Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245
Authors: Ricardo Fernandes; Sasha Mazzarello; Brian Hutton; Risa Shorr; Habeeb Majeed; Mohammed Fk Ibrahim; Carmel Jacobs; Michael Ong; Mark Clemons Journal: Support Care Cancer Date: 2016-05-05 Impact factor: 3.603
Authors: Mark Clemons; Demetrios Simos; Marta Sienkiewicz; Terry Ng; Labib Zibdawi; Bassam Basulaiman; Arif Awan; Dean Fergusson; Lisa Vandermeer; Deanna Saunders; Brian Hutton; Eitan Amir Journal: Support Care Cancer Date: 2021-03-19 Impact factor: 3.603
Authors: M Y Eileen C van der Stoep; Dagmar Berghuis; Robbert G M Bredius; Emilie P Buddingh; Alexander B Mohseny; Frans J W Smiers; Henk-Jan Guchelaar; Arjan C Lankester; Juliette Zwaveling Journal: Sci Rep Date: 2021-09-27 Impact factor: 4.379